Literature DB >> 3840022

Initial mechanistic studies with merbarone (NSC 336628).

D A Cooney, J M Covey, G J Kang, M Dalal, J B McMahon, D G Johns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3840022     DOI： 10.1016/0006-2952(85)90368-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  8 in total

1.  DNA cleavage and Trp53 differentially affect SINE transcription.

Authors:  Christy R Hagan; Charles M Rudin
Journal:  Genes Chromosomes Cancer       Date:  2007-03       Impact factor: 5.006

2.  Phase II trial of merbarone in patients with malignant brain tumors.

Authors:  U R Malik; J P Dutcher; G Caliendo; P Lasala; R Mitnick; P H Wiernik
Journal:  Med Oncol       Date:  1997 Sep-Dec       Impact factor: 3.064

3.  Nephrotoxicity of 5-(N-phenylcarboxamido)-2-thiobarbituric acid in the Fischer 344 rat.

Authors:  Y Nakagawa; R A Kramer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Merbarone: an antitumor agent entering clinical trials.

Authors:  A Glover; H G Chun; L M Kleinman; D A Cooney; J Plowman; C K Grieshaber; L Malspeis; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

5.  Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.

Authors:  E H Kraut; J Bendetti; S P Balcerzak; J H Doroshow
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

6.  Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.

Authors:  M Slavik; P Y Liu; E H Kraut; R B Natale; L E Flaherty; V K Sondak
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

7.  Phase II evaluation of merbarone in renal cell carcinoma.

Authors:  R C Flanigan; J H Saiers; M Wolf; E H Kraut; A Y Smith; B Blumenstein; E D Crawford
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

8.  Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Authors:  Anna Vavrova; Hana Jansova; Eliska Mackova; Miloslav Machacek; Pavlina Haskova; Lucie Tichotova; Martin Sterba; Tomas Simunek
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.